Clinical Drug Investigation

, Volume 11, Issue 3, pp 121–130 | Cite as

Clinical Efficacy of Brodimoprim in the Treatment of Acute Exacerbation of Chronic Bronchitis

A Meta-Analysis
  • Volker W. Rahlfs
  • Alberto Macciocchi
  • Tiziana Monti
Clinical Use
  • 5 Downloads

Summary

Brodimoprim is a diaminopyrimidine with a broad spectrum of antimicrobial activity in vitro, which includes activity against most common lower respiratory tract pathogens. The relative clinical efficacy of this agent was assessed in a meta-analysis of 16 randomised nonblind studies in more than 450 patients with acute exacerbations of chronic bronchitis. Physician-rated global clinical efficacy with brodimoprim was greater than with amoxicillin, and equivalent to that evinced for doxycycline. There was no evidence of intergroup differences in this measure between patients receiving brodimoprim and ampicillin or cefaclor, but equivalence was unproven. Overall, global clinical efficacy tended to favour brodimoprim in comparison with all other agents. Brodimoprim was as well tolerated as comparator agents when the results of studies using the same drugs were pooled (brodimoprim vs amoxicillin, ampicillin, cefaclor or doxycycline) or results of all studies were combined (brodimoprim vs all reference drugs). However, it was not possible to prove equivalence of tolerability in any of these comparisons because of the small number of patients. Based on these results, brodimoprim is a useful alternative to standard antimicrobial agents in the treatment of patients with acute exacerbations of chronic bronchitis.

Keywords

Adis International Limited Amoxicillin Doxycycline Acute Exacerbation Chronic Bronchitis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Reynolds HY. Chronic bronchitis and acute infectious exacerbations. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. New York: Churchill Livingston, 1990: 531–5Google Scholar
  2. 2.
    Committee on the Aetiology of Chronic Bronchitis. Definition and classification of chronic bronchitis for clinical and epidemiological purposes: report to the Medical Research Council. Lancet 1965; 1(7389): 775–9Google Scholar
  3. 3.
    Brown RB. Managing exacerbations of chronic bronchitis. J Respir Dis 1990; 2: 353–64Google Scholar
  4. 4.
    Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. Am J Med 1991; 91 Suppl. 6A: 87–92SCrossRefGoogle Scholar
  5. 5.
    MacFarlane JT. Acute infections of the lower respiratory tract. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine Vol. 2. Oxford: Oxford Medical Publications, 1990; 15.91–15.100Google Scholar
  6. 6.
    Cazzola M. Problems and prospectives in the antibiotic treatment of lower respiratory tract infections. Pulmon Pharmacol 1994; 7: 139–52CrossRefGoogle Scholar
  7. 7.
    Rabasseda X, Mealy N. Brodimoprim: a specific dihydrofolate reductase inhibitor with high tissue penetration, long half-life and broad spectrum antibacterial activity, suitable for oral administration. Drugs Today 1994; 30: 381–99Google Scholar
  8. 8.
    Moretti M, Marchioni CF, Bisetti A. Efficacy and tolerability of brodimoprim in respiratory tract infections. J Chemother 1993; 5: 517–20PubMedGoogle Scholar
  9. 9.
    Salmi HA. Brodimoprim in acute respiratory tract infections. J Chemother 1993; 5: 532–6PubMedGoogle Scholar
  10. 10.
    Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med 1986; 105: 429–35PubMedGoogle Scholar
  11. 11.
    Altman DG. Practical statistics for medical research. London: Chapman and Hall, 1991Google Scholar
  12. 12.
    Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27(5): 335–71PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen J. Statistical power for the behavioral sciences. New York: Academic Press, 1969Google Scholar
  14. 14.
    Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medical technology: the probability of a better outcome. Intern J Technol Assess Health Care 1988; 4: 637–42CrossRefGoogle Scholar
  15. 15.
    Gibaldi M. Meta-analysis. A review of its place in therapeutic decision making. Drugs 1993; 46: 805–18PubMedCrossRefGoogle Scholar
  16. 16.
    Verghese A, Ismail H. Acute exacerbations of chronic bronchitis. Postgrad Med 1994; 96: 75–89PubMedGoogle Scholar
  17. 17.
    Doern GV, Jorgensen JH, Thornsberry C, et al. Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. Diagn Microbiol Infect Dis 1986; 4(2): 95–107PubMedCrossRefGoogle Scholar
  18. 18.
    Struelens MJ, Nonhoff C, Lontie M, et al. In vitro activity of commonly used oral antimicrobial agents against community isolates of respiratory pathogens. Acta Clin Belg 1991; 46(5): 283–9PubMedGoogle Scholar
  19. 19.
    Scaglione F, Cogo R, Pintucci JP, et al. Brodimoprim concentrations in bronchial mucosa, bronchial secretions and middle ear effusions. J Chemother 1993; 5: 490–3PubMedGoogle Scholar
  20. 20.
    Amyes SGB. Comparative antibacterial spectrum of trimethoprim and brodimoprim. J Chemother 1993; 5: 417–21PubMedGoogle Scholar
  21. 21.
    Gallis HA. Acute bronchitis and acute exacerbations of chronic bronchitis: the role of new antimicrobials. Infect Dis Clin Prac 1994; 3: 81–6CrossRefGoogle Scholar
  22. 22.
    Greenland S. Quantitative methods in the analysis of epidemio-logical literature. Epidemiol Rev 1987; 9: 1–30PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Volker W. Rahlfs
    • 1
  • Alberto Macciocchi
    • 2
  • Tiziana Monti
    • 2
  1. 1.idv Datenanalyse und VersuchsplanungGauting/MünchenGermany
  2. 2.Products Development DepartmentHelsinn Healthcare SAPambio NorancoSwitzerland

Personalised recommendations